Core Viewpoint - The regulatory authorities have imposed severe penalties on *ST Gaohong Network Co., Ltd. for engaging in financial fraud over nine years, inflating revenues by nearly 20 billion yuan [1][4]. Group 1: Financial Fraud Details - From 2015 to 2023, *ST Gaohong inflated its revenue by approximately 19.8 billion yuan and profits by over 76.2 million yuan through fictitious trade activities [2][3]. - The fraudulent activities involved a closed-loop system with no actual goods flow, organized by the actual controller of a trading company [2]. - The company used inflated financial statements to raise funds, constituting fraudulent issuance of shares [3]. Group 2: Regulatory Actions - The China Securities Regulatory Commission (CSRC) plans to impose a fine of 135 million yuan on *ST Gaohong and an additional 26.75 million yuan on nine involved executives [4]. - The chairman and former general manager, Fu Jinglin, faces a dual penalty of 7.5 million yuan and a 10-year market ban [4]. - The CSRC has indicated that *ST Gaohong may face mandatory delisting due to serious violations, including fraudulent issuance of shares and false financial reporting [4][5]. Group 3: Industry Implications - The crackdown on *ST Gaohong reflects a zero-tolerance policy towards securities violations, aiming to maintain market order and protect investor rights [1][7]. - The regulatory environment has intensified, with an increase in criminal accountability for financial fraud among listed companies [7].

1月30日，证监会通报退市风险公司左江科技股份有限公司（简称"*ST左江"）财务造假案阶段性调查 进展情况。 2023年11月24日，证监会对*ST左江立案调查。证监会表示，现已初步查明，*ST左江2023年披露的财 务信息严重不实，涉嫌重大财务造假。该案目前正在调查过程中，证监会将尽快查明违法事实，依法严 肃处理。 因公司2022年年度经审计后的净利润(扣除非经常性损益前后孰低)为负值且营业收入低于1亿元，2023 年5月4日，公司被实施退市风险警示，股票简称由"左江科技"变更为"*ST左江"。在公司披星戴帽后， 股价不跌反涨，一路走高，最高达299.8元/股，成为史上最贵ST股。 【纠错】 【责任编辑:黄海荣 】 2023年12月1日，*ST左江公告称，因涉嫌信息披露违法违规，公司被证监会立案调查。此后，公司股 价大幅下跌。近日，*ST左江被游资炒作，股价再度翻倍上涨。1月23日晚间，公司发布公告称，公司 股票自2024年1月12日至1月22日连续六个交易日涨幅累计偏离110.78%，公司将对股票交易异常波动情 况进行核查，自1月24日开市起停牌，停牌时间不超5个交易日。 此次证监会的通报，再度向市场传递 ...

上海明伦律师事务所王智斌律师在接受《证券日报》记者采访时表示："当前，资本市场已经形成了行 政、刑事、民事立体追责，以保护投资者。通过提升违法成本，强化对财务造假等行为的查处力度，不 仅为后续投资者维权提供了基础，也可以净化资本市场生态。" 工信部信息通信经济专家委员会委员盘和林告诉《证券日报》记者："投资者的合法权益受到侵害时要 积极维护自身权益，监管部门也鼓励投资者通过诉讼实践，对各类违法责任主体追究民事赔偿责任。而 上市公司因为实际控制人、高管的违法违规行为受到损失的，可以依法向相关责任人追偿。" 此外，根据告知书认定的情况，公司披露的年度报告财务指标存在虚假记载，公司股票将被叠加实施其 他风险警示。 12月29日，苏州恒久光电科技股份有限公司（以下简称"ST恒久"）发布多个公告，公司被立案调 查之事有了最新进展。 根据中国证监会的查证，公司在2019年至2021年，连续3年有4期定期报告虚假记载，公司及相关责 任人被处罚，其中，ST恒久的控股股东、实际控制人余荣清拟被采取5年市场禁入措施。公司股票被叠 加实施其他风险警示。 同一天，ST恒久还因未就对外财务资助事项及时履行信息披露和监督管理义务、光导鼓 ...

此外，鸿达兴业通过虚增营业收入以及虚减营业成本、费用等方式虚增利润总额，导致2020年至 2022年年度报告、2023年半年度报告涉嫌存在虚假记载。上述期间虚增利润总额分别占公司当期披露利 润总额（绝对值）高达94.11%、94.42%、618.70%和12.84%。涉案期间虚增营业收入合计35.05亿元， 虚增利润总额合计40.78亿元。 已从深市退市一年的鸿达兴业股份有限公司（简称"鸿达兴业"，NQ400207）拟被重罚。江苏证监 局日前发出的《行政处罚事先告知书》显示，因涉嫌擅自改变可转债募集资金用途、多年财务造假、重 大诉讼、仲裁未依法披露等事项，江苏证监局拟对鸿达兴业、实控人及7名董监高人员开出合计5800万 元罚单。其中，公司拟被罚1850万元；实控人、董事长兼总经理周奕丰拟被罚2200万元，终身证券市场 禁入；财务总监林桂生拟被罚600万元，10年证券市场禁入。 对于擅自改变可转债募集资金用途、财务造假等严重违法行为，监管部门对鸿达兴业及周奕丰均拟 实施顶格处罚。监管部门认为，周奕丰组织、指使公司在相关定期报告中编造、篡改重要财务数据，严 重扰乱证券市场秩序，组织、指使公司擅自变更募集资金用途； ...

Core Viewpoint - *ST Tianmao (000627.SZ), controlled by Liu Yiqian, has announced its intention to voluntarily delist from the stock market due to its inability to disclose financial reports for 2024 and Q1 2025, which could lead to mandatory delisting by regulatory authorities [1][2][4]. Group 1: Company Actions and Financial Situation - The board of *ST Tianmao has approved a proposal to terminate the company's stock listing and transfer to the National Equities Exchange and Quotations (NEEQ) after delisting [1]. - Liu Yiqian and his wife control over 66% of the company's shares, with an estimated cost of 2.6 billion yuan based on an exercise price of 1.6 yuan per share [2]. - The company has set up mechanisms to protect dissenting shareholders, offering cash options to all A-share shareholders except for the actual controller Liu Yiqian [1]. Group 2: Investor Concerns and Market Reactions - Investors have expressed concerns that the company intentionally suppressed stock prices to trigger delisting rules, leading to significant losses for shareholders [3]. - As of now, *ST Tianmao has approximately 111,900 shareholders, and the stock price has been drastically reduced, with a valuation of 0.27 yuan per share by a fund company, down over 90% from the pre-suspension price of 2.74 yuan [3]. - The stock price reached a limit-up of 1.52 yuan on August 11, attributed to the exercise price being higher than the suspended price [3]. Group 3: Financial Reporting Issues - The company has been under investigation by the China Securities Regulatory Commission (CSRC) for failing to disclose periodic reports on time [4]. - The inability to obtain auditor approval for financial reports is typically linked to discrepancies in financial data or insufficient evidence [5]. - Despite generating stable revenue figures over the years, the company relies heavily on its subsidiary, Guohua Life Insurance, which has reported a decline in premium income [5][6]. Group 4: Investment Strategies and Risks - Guohua Life Insurance has been criticized for its high policy surrender rates, with significant amounts returned to policyholders over the past three years [6]. - The company has engaged in unconventional investment strategies, primarily through trust plans, raising questions about its operational model as an insurance company [8]. - Guohua Life's investments in real estate and trust loans have raised concerns about compliance with regulatory standards for insurance fund investments [11][15]. Group 5: Leadership and Future Outlook - Liu Yiqian has begun liquidating personal assets, including art collections, to raise funds amid the company's financial struggles [23]. - The loss of control over Changjiang Securities marks a significant shift for Liu Yiqian, reducing his influence in the financial sector [24][25]. - The potential delisting of *ST Tianmao raises questions about the company's future and its ability to meet the requirements for trading on the NEEQ [26].

Core Viewpoint - The regulatory authority has imposed severe penalties on *ST Gaohong (000851) for engaging in financial fraud over nine years, inflating revenues by nearly 20 billion yuan, reflecting a zero-tolerance stance towards securities violations [1][4]. Group 1: Financial Fraud Details - From 2015 to 2023, *ST Gaohong inflated its revenue by approximately 19.8 billion yuan and profits by over 76.2 million yuan through fictitious trade activities [2][3]. - The fraudulent activities involved a closed-loop system where suppliers and customers were orchestrated by Jiang Qing, with no actual goods being exchanged [2]. - The company also misused inflated financial statements to raise funds, constituting fraudulent issuance during its non-public stock offering in 2020, which raised 1.25 billion yuan [3]. Group 2: Regulatory Actions - The China Securities Regulatory Commission (CSRC) plans to impose a fine of 135 million yuan on *ST Gaohong and an additional 26.75 million yuan on nine involved executives, including a 7.5 million yuan fine and a 10-year market ban for the chairman [4]. - Jiang Qing, the actual controller of Nanjing Qingya, will also face a 7 million yuan fine and a 10-year market ban for his role in the fraudulent activities [4]. - The company has issued a risk warning regarding the potential for mandatory delisting due to serious violations, including fraudulent issuance and false reporting in annual reports [4][5]. Group 3: Industry Implications - The crackdown on financial fraud is part of a broader regulatory effort to maintain market integrity and protect investors, with an increasing number of companies and individuals facing criminal charges for similar offenses [6][7]. - The regulatory environment has become more stringent, with a focus on creating a comprehensive deterrent system against financial misconduct, enhancing the overall standard of the capital market [7].

Core Viewpoint - The article discusses serious allegations against Huaxi Biological, including financial mismanagement, information disclosure issues, bond issuance fraud, and tax evasion, as revealed by a whistleblower who claims to be a former executive of the company [2][5][22]. Summary by Sections Whistleblower Allegations - The whistleblower, identified as David, has released a series of videos detailing alleged financial irregularities at Huaxi Biological, including a lack of proper financial management and low R&D investment [3][5][22]. - David claims that the financial team is poorly organized, lacking basic financial literature and effective data integration, which raises concerns about the company's governance [10][14][18]. Financial Mismanagement - David noted that R&D investment at Huaxi Biological is only 5% of revenue, significantly lower than the industry standard of over 25% [18]. - He reported that the CFO's office was disorganized, with outdated organizational charts and a lack of professional financial resources [14][16]. Specific Allegations of Fraud - The article outlines several specific allegations, including: 1. **False Promises**: Huaxi Xinyu allegedly concealed significant information during its IPO process in 2015, including the undisclosed holding of 30 million shares [23]. 2. **Financial Fabrication**: In 2017, Huaxi Xinyu reportedly fabricated financial statements, claiming 1.17 billion in revenue while the actual figure was only 1.23 million [23]. 3. **Bond Fraud**: The company allegedly misled the Shenzhen Stock Exchange to secure bond issuance approvals totaling 1.8 billion [23]. 4. **Tax Evasion**: Huaxi Xinyu is accused of orchestrating a scheme to evade 57.72 million in taxes through investment strategies exploiting tax exemptions [23]. IPO and Regulatory Issues - Despite ongoing investigations into Huaxi Xinyu's practices, Huaxi Biological successfully went public in 2019, with its IPO prospectus allegedly omitting critical information regarding the aforementioned fraudulent activities [24][31]. - The company has faced scrutiny from regulatory bodies, including the China Securities Regulatory Commission, which previously issued warnings regarding financial discrepancies [29][31]. Company Response - Huaxi Biological has publicly denied the allegations, claiming that the whistleblower's statements are fabricated and malicious, and has initiated legal actions against the individual [28][32]. - The company asserts that previous investigations by regulatory authorities found no evidence of fraud or significant information disclosure violations [31].

Core Viewpoint - *ST Gaohong has been implicated in a massive financial fraud spanning nine years, leading to a significant drop in stock price and potential delisting due to major violations of regulations [2][7][9]. Financial Fraud Details - The company inflated its revenue by nearly 20 billion yuan through fictitious trade activities from 2015 to 2023, with total inflated revenue amounting to 19.876 billion yuan and inflated profit totaling 76.2259 million yuan [4][6]. - Specific years of inflated revenue include: - 2015: 6.94 million yuan (9.34%) - 2016: 24.52 million yuan (28.27%) - 2017: 24.20 million yuan (26.97%) - 2018: 32.59 million yuan (35.18%) - 2019: 56.34 million yuan (49.38%) - 2020: 24.83 million yuan (35.38%) - 2021: 18.05 million yuan (21.11%) - 2022: 7.35 million yuan (10.72%) - 2023: 3.94 million yuan (6.65%) [5][6]. Regulatory Actions - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for fraudulent issuance of stocks in 2020, which involved false data from 2018 to 2020 [2][6]. - Due to the ongoing investigations and findings, *ST Gaohong's stock has been marked with a "ST" label, indicating it is under special treatment due to financial irregularities [8][9]. Audit Opinions - The company has faced consecutive years of adverse audit opinions from different accounting firms, indicating significant issues with its financial reporting and internal controls [8]. - The 2023 audit report highlighted uncertainties regarding the company's ability to continue as a going concern [8]. Industry Context - Since 2025, a total of 24 companies have been delisted, with several facing similar financial misconduct issues, indicating a broader trend of regulatory scrutiny in the market [10]. - Other companies currently under investigation for major violations include *ST Suwu, *ST Zitian, and others, reflecting systemic issues within the industry [11].

Group 1 - Company *ST Gao Hong (000851.SZ) has been placed under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to a trading halt with shares dropping to 2.1 yuan and over 4 million shares on hold [1] - The CSRC's notice indicates that the company engaged in fraudulent issuance of shares during its non-public offering in 2020, and its annual reports from 2015 to 2023 contain false records, potentially leading to mandatory delisting [1] - Investigations revealed that *ST Gao Hong inflated its revenue and profits through fictitious trade activities, resulting in a total inflated revenue of 19.876 billion yuan and inflated profit of 76.2259 million yuan from 2015 to 2023 [1] Group 2 - The CSRC plans to impose a fine of 160 million yuan on the responsible parties and an additional 7 million yuan on third parties involved in the fraudulent activities [1]

好消息！方正电机的股民，可以找老板赔钱了！ 去年，方正电机因为财务造假和信息披露违规，被有关部门处罚。今年开始，因此受到损失的股民，可以登机索赔了。 想当初，方正电机的股价，在高峰时一跃至38.6元，但短暂的辉煌过后，就一路下滑，竟再无反弹的迹象。 这实在无法不让人多想：这是不是张敏精心谋划的一场布局。 说到方正电机，业内的成绩是有目共睹的。 1991年，方正电机成立。 从最初只有5万启动资金、40多名员工和200平方米的租用厂房开始，方正人靠着不屈不挠的精神，打造出了属于自己的荣誉： 2000年，成为省级"五个一批"重点骨干企业； 2001年，成为省级"100个拳头产品骨干企业"； 之后更是荣誉不断，接连被评定为"省高新技术企业""最具成长性中型企业100佳"等等。 按理说，方正电机作为国内电机领域的翘楚，应该是难以上车的白马股，怎么反而成了股市的一大天坑？ 而就在其股价暴跌后，3万多接盘侠被牢牢套死，前董事长张敏却套现8个亿，精准踩点离场。 作为新能源驱动电机生产商，方正电机在国内的装机量也是遥遥领先，合作过的企业有蔚来、五菱这些我们都熟知的汽车品牌。 不只是在国内，方正电机的产品更是出口全球70多个国家 ...